KIR2DL1 and acute myeloid leukemia: This effect was similar in patients with AML or ALL and was even higher when patients received a KIR2DL1-R245–positive graft with HLA-C receptor–ligand mismatch in terms of overall survival and compared with those who received a KIR2DL1-C245 homozygous graft (98).